European Pricing: Conundrum or Microcosm for the Future?
Executive SummaryEuropean drug pricing is complex and outdated, but it nevertheless comes closest to what the future global drug pricing environment may look like, argues IMS Global Consulting.
You may also be interested in...
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.